← KEWAUNEE SCIENTIFIC CORP /DE/
| Annual Trend | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $128.6m |
$138.6m
+7.72%
|
$158.1m
+14.07%
|
$146.6m
-7.28%
|
$147.5m
+0.68%
|
$147.5m
-0.05%
|
$168.9m
+14.51%
|
$219.5m
+29.98%
|
$203.8m
-7.17%
|
$240.5m
+18.02%
|
$282.0m
+17.27%
|
|
| Cost of Revenue | $104.9m |
$112.0m
+6.70%
|
$126.0m
+12.58%
|
$121.2m
-3.81%
|
$124.1m
+2.38%
|
$123.5m
-0.51%
|
$144.7m
+17.15%
|
$183.9m
+27.14%
|
$151.7m
-17.51%
|
$171.6m
+13.12%
|
$201.6m
+17.45%
|
|
| Cost of products sold | $112.0m |
$126.0m
+12.58%
|
$121.2m
-3.81%
|
$124.1m
+2.38%
|
$123.5m
-0.51%
|
$144.7m
+17.15%
|
$183.9m
+27.14%
|
$151.7m
-17.51%
|
$171.6m
+13.12%
|
$201.6m
+17.45%
|
— | |
| Gross Profit | $23.7m |
$26.6m
+12.23%
|
$32.0m
+20.34%
|
$25.3m
-20.93%
|
$23.4m
-7.47%
|
$24.0m
+2.42%
|
$24.2m
+0.95%
|
$35.6m
+46.94%
|
$52.1m
+46.26%
|
$68.9m
+32.29%
|
$80.4m
+16.82%
|
|
| Research and Development Expense | $1.2m | $1.2m | $1.5m | $1.6m | $1.8m | $1.4m | $990k | $1.0m | $920k | $919k | — | |
| Operating Lease, Expense | — | — | — | $2.4m | $2.4m | $2.9m | $3.1m | $3.3m | $3.5m | $4.4m | — | |
| Operating Expenses | $18.0m | $20.1m | $22.9m | $23.2m | $25.8m | $25.3m | $26.8m | $30.2m | $33.8m | $51.1m | $63.7m | |
| Operating Income (Loss) | $5.7m |
$6.5m
+14.81%
|
$9.1m
+38.89%
|
$2.1m
-76.76%
|
($2.3m)
-211.03%
|
($1.3m)
+43.88%
|
($2.6m)
-98.18%
|
$5.4m
+305.67%
|
$18.3m
+240.81%
|
$17.8m
-2.86%
|
$16.7m
-5.88%
|
|
| Interest Expense | $306k | $292k | $299k | $367k | $493k | $389k | $632k | $1.7m | $1.8m | ($3.9m) | $3.9m | |
| Defined Benefit Plan, Net Periodic Benefit Cost (Credit), Gain (Loss) Due to Settlement | — | — | — | — | — | — | — | ($4.0m) | ($4.0m) | — | — | |
| Interest Expense (non-operating) | — | — | — | — | — | — | — | — | $3.2m | $3.2m | $3.9m | |
| Other Income | $347k | $496k | $693k | $389k | $426k | $241k | $400k | $939k | $814k | $240k | — | |
| Other income, net | $496k | $693k | $389k | $426k | $241k | $400k | $939k | $814k | $240k | $880k | $880k | |
| Income (Loss) from Continuing Operations before Income Taxes, Domestic | — | — | — | — | — | — | — | — | — | $6.8m | $13.7m | |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest | $5.7m | $6.7m | $9.5m | $2.1m | ($2.9m) | ($2.6m) | ($2.5m) | $4.5m | $13.1m | $14.8m | $13.7m | |
| Total earnings before income tax expense | $6.7m | $9.5m | $2.1m | ($2.9m) | ($2.6m) | ($2.5m) | $4.5m | $13.1m | $14.8m | $13.7m | — | |
| Current Income Tax Expense (Benefit) | $2.2m | $2.5m | $3.4m | $419k | ($673k) | $748k | $3.4m | $2.6m | $5.1m | $5.4m | $3.3m | |
| Income tax expense | $2.1m | $4.1m | $446k | $1.8m | $990k | $3.5m | $3.1m | ($5.9m) | $3.2m | $3.3m | $3.3m | |
| Income Tax Expense (Benefit) | $1.9m | $2.1m | $4.1m | $446k | $1.8m | $990k | $3.5m | $3.1m | ($5.9m) | $3.2m | $3.3m | |
| Net earnings | $4.6m |
$5.4m
+16.13%
|
$1.7m
-68.54%
|
($4.6m)
-373.93%
|
($3.6m)
+21.99%
|
($6.0m)
-66.43%
|
$1.4m
+122.64%
|
$19.1m
+1302.28%
|
$11.6m
-39.22%
|
$10.5m
-9.65%
|
$9.6m
-8.09%
|
|
| Less: net earnings attributable to the non-controlling interest | $105k | $177k | $159k | $63k | $65k | $123k | $621k | $304k | $178k | $847k | — | |
| Net earnings attributable to Kewaunee Scientific Corporation | $4.5m | $5.2m | $1.5m | ($4.7m) | ($3.7m) | ($6.1m) | $738k | $18.8m | $11.4m | $9.6m | — | |
| Net Income (Loss) Attributable to Parent | $3.8m |
$4.5m
+18.75%
|
$5.2m
+14.91%
|
$1.5m
-70.53%
|
($4.7m)
-406.54%
|
($3.7m)
+21.66%
|
($6.1m)
-66.83%
|
$738k
+112.05%
|
$18.8m
+2441.06%
|
$11.4m
-39.18%
|
$9.6m
-15.67%
|
|
| Net Income (Loss) Attributable to Noncontrolling Interest | $75k | $105k | $177k | $159k | $63k | $65k | $123k | $621k | $304k | $178k | $9.6m | |
| Earnings Per Share, Basic | $1.43 | $1.67 | $1.91 | $0.56 | ($1.70) | ($1.33) | ($2.20) | $0.26 | $6.51 | $3.98 | $3.36 | |
| Earnings Per Share, Diluted | $1.42 | $1.66 | $1.87 | $0.55 | ($1.70) | ($1.33) | ($2.20) | $0.25 | $6.38 | $3.83 | $3.22 | |
| Weighted Average Number of Shares Outstanding, Basic | 2.7m | 2.7m | 2.7m | 2.7m | 2.8m | 2.8m | 2.8m | 2.8m | 2.9m | 2.9m | 2.9m | |
| Basic (in shares) | $2.7m | $2.7m | $2.7m | $2.8m | $2.8m | $2.8m | $2.8m | $2.9m | $2.9m | $2.9m | $2.9m | |
| Weighted Average Number of Shares Outstanding, Diluted | 2.7m | 2.7m | 2.8m | 2.8m | 2.8m | 2.8m | 2.8m | 2.9m | 2.9m | 3.0m | 3.0m | |
| Additional Financial Items | ||||||||||||
| Goodwill, Impairment Loss | — | — | — | — | — | — | — | — | $0 | $0 | — | |
| Operating earnings | $6.5m |
$9.1m
+38.89%
|
$2.1m
-76.76%
|
($2.3m)
-211.03%
|
($1.3m)
+43.88%
|
($2.6m)
-98.18%
|
$5.4m
+305.67%
|
$18.3m
+240.81%
|
$17.8m
-2.86%
|
$16.7m
-5.88%
|
— |